• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
    • 2022 Events
  • Contact Us

New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option

June 1, 2021 by tmurphy

Additionally, an expert physician panel in Europe reached consensus and published a new recommended fibroid treatment algorithm with transcervical radiofrequency ablation (Sonata) at the forefront

Redwood City, CA, June 1, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of guidelines by the American College of Obstetricians and Gynecologists (ACOG) that support the use of transcervical radiofrequency ablation as a minimally invasive, uterine preserving option for women suffering from symptomatic uterine fibroids.1  This is a significant achievement for Gynesonics’ Sonata® System, the only existing technology for transcervical radiofrequency ablation of fibroids.

“The updated guidelines represent ACOG’s commitment to educate and support therapies aligning treatments with the goals of patient care,” said David Toub, M.D., M.B.A., FACOG, Gynesonics’ Medical Director.  “We are pleased that ACOG included transcervical radiofrequency ablation of fibroids in their Practice Bulletin.  This is recognition of transcervical radiofrequency ablation’s effectiveness in improving the quality of life for women suffering from uterine fibroids, and in reducing uterine fibroid volume.  This comes on the heels of the two-part expert consensus recommendation of a new fibroid treatment algorithm in Europe incorporating transcervical radiofrequency ablation. 2  The Sonata System’s transcervical approach, associated with safety, effectiveness and short recovery time, is rapidly gaining recognition and acceptance among global leaders in minimally invasive gynecologic surgery.”

In addition to the ACOG guidelines, a review of fibroid treatment options by a panel of German, Swiss and Austrian gynecological surgical experts was conducted, and consensus was reached recommending a new treatment algorithm where transcervical radiofrequency ablation was noted as the first line option to be offered in most fibroid types for women who wish to preserve their uterus.2  The panel of fibroid experts, whom together have experience with over 900 Sonata procedures in their facilities, includes Prof. Dr. med Thomas Römer, Evangelisches Klinikum Köln-Weyertal, in Cologne, Germany; Dr. med. Ladina Christoffel, Spital Oberengadin, Samedan, Switzerland; and Prof. Dr. med. Ricardo Felberbaum, Klinikverbund Kempten-Oberallgäu, Kempten, Germany.

“I’m particularly pleased to see ACOG recognize the efficacy of transcervical radiofrequency ablation of fibroids.  I believe the ability of this incisionless, transcervical approach to treat larger and deeper fibroids that are highly associative to heavy menstrual bleeding is very important, and is a groundbreaking advancement for women’s healthcare,” said James Greenberg M.D., FACOG , Chief of Gynecology, Brigham and Women’s Faulkner Hospital  and Associate Professor, Harvard Medical School in Boston.  “Transcervical radiofrequency ablation of fibroids with the Sonata System is very approachable for gynecologic surgeons, which will make this option more accessible to physicians and thus offered to a greater number of women.  Patients are asking for less invasive options and Sonata meets this need by providing an incisionless, quick recovery procedure that results in durable symptom relief.  I anticipate commercial insurance payers accelerating their efforts to provide coverage for Sonata and thereby recognize, as ACOG has, the importance of this treatment option for women.  I look forward to the possibility of additional involvement by ACOG in support of this procedure.”

For more information on the Sonata System, go to www.gynesonics.com.

References

  1. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. Obstet Gynecol. 2021;1131-1133. acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/06/management-of-symptomatic-uterine-leiomyomas.
  2. Römer T, Bends R, Christoffel L et al. Behandlung von symptomatischen Myomen mit der transzervikalen ultraschallgesteuerten Radiofrequenzablation-Indikationen, Durchführung, Ergebnisse und Komplikationen-Expertenkonsensus 2020. Teil 2: Die transzervikale Radiofrequenzablation (TRFA) – Methode, Indikationen, Ergebnisse und Vergleich mit anderen Therapien. Frauenarzt 2021;62:162-168. (English translation at gynesonics.com)

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer.  The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment.  The Sonata system provides incision-free transcervical access for a uterus-preserving fibroid treatment.  This intrauterine approach is designed to avoid the peritoneal cavity, and most side effects are typically minor and temporary.  The Sonata System is CE marked and is approved for sale in the European Union, the United Kingdom and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications.  Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.  Gynesonics headquarters is in Redwood City, CA.

# # #

Company Contact:

Stan Van Gent, Senior Director, Global Marketing, Gynesonics, svangent@gynesonics.com, (661) 388-6380

Media Contact:

David Gutierrez, Dresner Corporate Services, dgutierrez@dresnerco.com, (312) 780-7204

 

Filed Under: Press Releases

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. J

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

Gynesonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Show details
Name Provider Purpose Expiration
moove_gdpr_popup Gynesonics via Moove GDPR Plugin This is used to save your cookie settings for this website. 12 months
__cf_bm Cloudflare The __cf_bm cookie is a cookie necessary to support Cloudflare Bot Management. As part of their bot management service, this cookie helps manage incoming traffic that matches criteria associated with bots. Cookie is set on websites using Cloudfare and it is related to rate limiting policies. less than 12m
Analytics Cookies

This website uses analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Show details
Name Provider Purpose Expiration
_ga, _gat, _gid, _ga_* Google Analytics These cookies enable analytics features in our suite (e.g., distinguish users, remember traffic information, and determine the start and end of a session). They are set for analytics measures on our website. We can take a timestamp of your website visit, track the source (e.g. search engine) you used to access our website, and the number of times you visit our website. 1-12 months
_gcl_au, _gat_gtag_UA_* Google Tag Manager These cookies helps us to enable functional requests on our website, such as the communications between our website and resources such as style, fonts, and images. As a cookie related to our Tag Manager, it collects your interaction with our resources (e.g. clicks and views) to help us understand your behavior on our website as well as to improve our aggregated analysis from interactions and campaigns. 1-12 months